Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease

Preeclampsia is a clinical syndrome defined as the new onset of hypertension and proteinuria during the second half of pregnancy.1 It afflicts 3% to 5% of pregnancies and is a leading cause of maternal mortality, especially in developing countries.2,3 Because the only known remedy is delivery of the placenta, in developed countries preeclampsia is an important cause of premature delivery, usually medically indicated for the benefit of the mother. This results in infant morbidity and substantial healthcare expenditure.4 Despite the considerable morbidity and mortality, the cause of preeclampsia has remained enigmatic. Both hypertension and proteinuria implicate the endothelium as the target of the disease. The hypertension of preeclampsia is characterized by peripheral vasoconstriction and decreased arterial compliance.5,6 The proteinuria of preeclampsia is associated with a pathognomonic renal lesion known as glomerular endotheliosis, in which the endothelial cells of the glomerulus swell and endothelial fenestrations are lost.7,8 Podocyturia has been recently associated with preeclampsia during clinical disease9; however, whether this is the cause or effect of proteinuria is unknown. The glomerular filtration rate is decreased compared with normotensive pregnant women; in rare cases, acute renal failure may develop. Preeclampsia is a systemic vascular disorder that may also affect the liver and the brain in the mothers. When the liver is involved, women may present with abdominal pain, nausea, vomiting, and elevated liver enzymes. Pathological examination of the liver reveals periportal and sinusoidal fibrin deposition and, in more extreme cases, hemorrhage and necrosis.10 The severe preeclampsia variant HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) occurs in ≈20% of women with severe preeclampsia,11 and is named not only for the liver involvement, but also for the disorder of the coagulation system that develops.12 Approximately 20% of …

[1]  L. Vatten,et al.  Preeclampsia, Soluble Fms-like Tyrosine Kinase 1, and the Risk of Reduced Thyroid Function: Nested Case-Control and Population-based Study , 2011 .

[2]  R. Romero,et al.  Circulating angiogenic and antiangiogenic factors in women with eclampsia. , 2011, American journal of obstetrics and gynecology.

[3]  I. Barshack,et al.  Metabolic , Endocrine and Genitourinary Pathobiology Effects of Hypoxia-Inducible Factor-1 Overexpression in Pregnant Mice Possible Implications for Preeclampsia and Intrauterine Growth Restriction , 2010 .

[4]  J. Kingdom,et al.  Vascular Dysfunction in Women With a History of Preeclampsia and Intrauterine Growth Restriction: Insights Into Future Vascular Risk , 2010, Circulation.

[5]  Randy J Read,et al.  A redox switch in angiotensinogen modulates angiotensin release , 2010, Nature.

[6]  L. Vatten,et al.  Hypertension in Pregnancy and Later Cardiovascular Risk: Common Antecedents? , 2010, Circulation.

[7]  Y. Jang,et al.  Soluble fms-like tyrosine kinase-1 and the progression of carotid intima-media thickness – 24-month follow-up study –. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[8]  C. Sartori,et al.  Pulmonary and Systemic Vascular Dysfunction in Young Offspring of Mothers With Preeclampsia , 2010, Circulation.

[9]  A. Hingorani,et al.  Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension , 2010, Circulation.

[10]  K. Lim,et al.  The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome , 2010, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[11]  Mitsuaki Suzuki,et al.  Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia , 2010, Hypertension Research.

[12]  N. Brown,et al.  Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy , 2010, Hypertension.

[13]  R. Levine,et al.  How does smoking reduce the risk of preeclampsia? , 2010, Hypertension.

[14]  G. Saade,et al.  Vitamins C and E to prevent complications of pregnancy-associated hypertension. , 2010, The New England journal of medicine.

[15]  S. Karumanchi,et al.  Placental Vasculature in Health and Disease , 2010, Seminars in thrombosis and hemostasis.

[16]  J. Folkman,et al.  Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. , 2010, The Journal of pediatrics.

[17]  Trimble,et al.  Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia. , 2010, American journal of obstetrics and gynecology.

[18]  J. Dudenhausen,et al.  An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. , 2010, American journal of obstetrics and gynecology.

[19]  S. Karumanchi,et al.  Recombinant Vascular Endothelial Growth Factor 121 Infusion Lowers Blood Pressure and Improves Renal Function in Rats With Placental Ischemia-Induced Hypertension , 2010, Hypertension.

[20]  A. Gruber,et al.  Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model , 2009, Journal of cellular and molecular medicine.

[21]  B. Sibai,et al.  Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. , 2010, American journal of obstetrics and gynecology.

[22]  L. Vatten,et al.  Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study , 2009, BMJ : British Medical Journal.

[23]  R. Romero,et al.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[24]  H. Pavenstädt,et al.  The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[25]  John C Chappell,et al.  Local guidance of emerging vessel sprouts requires soluble Flt-1. , 2009, Developmental cell.

[26]  K. Boström,et al.  Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. , 2009, Blood.

[27]  H. Hurwitz,et al.  Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression , 2009, Hypertension.

[28]  Kang Z. Liu,et al.  A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. , 2009, The Journal of clinical endocrinology and metabolism.

[29]  B. Sibai,et al.  Hypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the Mother , 2009, Hypertension.

[30]  B. Sibai,et al.  Diagnosis and management of atypical preeclampsia-eclampsia. , 2009, American journal of obstetrics and gynecology.

[31]  L. Poston,et al.  World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre‐eclampsia in populations of low nutritional status from developing countries , 2009, BJOG : an international journal of obstetrics and gynaecology.

[32]  C. Berg,et al.  Overview of Maternal Morbidity During Hospitalization for Labor and Delivery in the United States: 1993–1997 and 2001–2005 , 2009, Obstetrics and gynecology.

[33]  M. Saint-Geniez,et al.  TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature , 2009, PloS one.

[34]  L. Florea,et al.  Novel splice variants of sFlt1 are upregulated in preeclampsia. , 2009, Placenta.

[35]  S. Wen,et al.  Utilization of Health Care Services of Pregnant Women Complicated by Preeclampsia in Ontario , 2009, Hypertension in pregnancy.

[36]  I. Sargent,et al.  Circulating Platelet-derived and Placenta-derived Microparticles Expose Flt-1 in Preeclampsia , 2008, Reproductive Sciences.

[37]  R. Levine,et al.  Circulating soluble endoglin and placental abruption , 2008, Prenatal diagnosis.

[38]  Tiejuan Mi,et al.  Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice , 2008, Nature Medicine.

[39]  J. Tanus-Santos,et al.  Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia , 2008, Hypertension.

[40]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[41]  E. Norwitz,et al.  Fractional Excretion of Tumor Necrosis Factor-&agr; in Women With Severe Preeclampsia , 2008, Obstetrics and gynecology.

[42]  S. Yagel,et al.  A Novel Human-Specific Soluble Vascular Endothelial Growth Factor Receptor 1: Cell Type-Specific Splicing and Implications to Vascular Endothelial Growth Factor Homeostasis and Preeclampsia , 2008, Circulation research.

[43]  Liang Xie,et al.  Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia , 2008, Nature.

[44]  R. Ness,et al.  C-Reactive Protein Is Elevated 30 Years After Eclamptic Pregnancy , 2008, Hypertension.

[45]  M. Petri,et al.  Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[46]  G. Demetri,et al.  A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. , 2008, Journal of the National Cancer Institute.

[47]  N. Himes,et al.  VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma , 2008, The Journal of experimental medicine.

[48]  T. Konno,et al.  Maternal hypoxia activates endovascular trophoblast cell invasion. , 2008, Developmental biology.

[49]  F. Schatz,et al.  Pre‐eclampsia is associated with dendritic cell recruitment into the uterine decidua , 2008, The Journal of pathology.

[50]  B. Sibai,et al.  Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. , 2008, Obstetrics and gynecology.

[51]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[52]  J. Granger,et al.  Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 Expression , 2007, Hypertension.

[53]  A. Hingorani,et al.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[54]  N Stephen Pollitt,et al.  Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia , 2007, Hypertension.

[55]  S. Karumanchi,et al.  The glomerular injury of preeclampsia. , 2007, Journal of the American Society of Nephrology : JASN.

[56]  P. McKenzie,et al.  Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. , 2007, Kidney international.

[57]  Asif Ahmed,et al.  Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1 , 2007, Circulation.

[58]  G. Saade,et al.  The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. , 2007, American journal of obstetrics and gynecology.

[59]  A. Baschat,et al.  Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. , 2007, American journal of perinatology.

[60]  K. Bailey,et al.  Urinary podocyte excretion as a marker for preeclampsia. , 2007, American journal of obstetrics and gynecology.

[61]  M. Wolf,et al.  Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia , 2007, Hypertension.

[62]  K. Lim,et al.  Circulating Levels of the Antiangiogenic Marker Soluble FMS-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia , 2007, Diabetes Care.

[63]  S. Karumanchi,et al.  Endothelial Dysfunction: A Link Among Preeclampsia, Recurrent Pregnancy Loss, and Future Cardiovascular Events? , 2007, Hypertension.

[64]  Caroline A Crowther,et al.  Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study , 2006, BMJ : British Medical Journal.

[65]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[66]  J. Thurman,et al.  Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction , 2006, The Journal of experimental medicine.

[67]  J. Hanna,et al.  Decidual NK cells regulate key developmental processes at the human fetal-maternal interface , 2006, Nature Medicine.

[68]  F. Epstein,et al.  Circulating Angiogenic Factors and Placental Abruption , 2006, Obstetrics and gynecology.

[69]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[70]  L. Poston,et al.  Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial , 2006, The Lancet.

[71]  F. Epstein,et al.  Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. , 2006, American journal of obstetrics and gynecology.

[72]  A. Coomarasamy,et al.  Accuracy of serum uric acid in predicting complications of pre‐eclampsia: a systematic review , 2006, BJOG : an international journal of obstetrics and gynaecology.

[73]  G. Pacini,et al.  Preeclampsia in Lean Normotensive Normotolerant Pregnant Women Can Be Predicted by Simple Insulin Sensitivity Indexes , 2006, Hypertension.

[74]  M. Saint-Geniez,et al.  Vascular endothelial growth factor localization in the adult. , 2006, The American journal of pathology.

[75]  G. Krikun,et al.  Regulation of monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha and interleukin-1beta in first trimester human decidual cells: implications for preeclampsia. , 2006, The American journal of pathology.

[76]  Betty Y. Y. Tam,et al.  VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[77]  C. Ozcan,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[78]  J. Granger,et al.  Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. , 2006, Methods in molecular medicine.

[79]  M. Schull,et al.  Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study , 2005, The Lancet.

[80]  K. Lim,et al.  Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia , 2005, Hypertension.

[81]  Michael Simons,et al.  Role of Angiogenesis in Cardiovascular Disease : a Critical Appraisal , 2022 .

[82]  M. Wolf,et al.  Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. , 2005, Placenta.

[83]  R. Ness,et al.  Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. , 2005, American journal of obstetrics and gynecology.

[84]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[85]  Kirsten Duckitt,et al.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies , 2005, BMJ : British Medical Journal.

[86]  G. Mires,et al.  In Preeclampsia, the Circulating Factors Capable of Altering In Vitro Endothelial Function Precede Clinical Disease , 2005, Hypertension.

[87]  B. Sibai Diagnosis, prevention, and management of eclampsia. , 2005, Obstetrics and gynecology.

[88]  K. Lim,et al.  Urinary placental growth factor and risk of preeclampsia. , 2005, JAMA.

[89]  R. Romero,et al.  Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[90]  E. Norwitz,et al.  Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. , 2004, American journal of obstetrics and gynecology.

[91]  J. Norman The nature of glomerular dysfunction in preeclampsia , 2005 .

[92]  M. Wolf,et al.  Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. , 2004, The Journal of clinical endocrinology and metabolism.

[93]  S. Kōzuma,et al.  Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. , 2004, Endocrinology.

[94]  Asif Ahmed,et al.  Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia , 2004, Circulation research.

[95]  M. Carrington,et al.  Combinations of Maternal KIR and Fetal HLA-C Genes Influence the Risk of Preeclampsia and Reproductive Success , 2004, The Journal of experimental medicine.

[96]  M. Goumans,et al.  Endoglin promotes endothelial cell proliferation and TGF‐β/ALK1 signal transduction , 2004, The EMBO journal.

[97]  L. Poston,et al.  Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. , 2004, Hypertension.

[98]  N. Berkane,et al.  Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. , 2004, Clinical chemistry.

[99]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[100]  R. Romero,et al.  Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. , 2004, American journal of obstetrics and gynecology.

[101]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[102]  Robert N. Taylor,et al.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.

[103]  J. Foidart,et al.  Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.

[104]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.

[105]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[106]  N. Sattar,et al.  Classic and Novel Risk Factor Parameters in Women With a History of Preeclampsia , 2003, Hypertension.

[107]  Christoph Dehio,et al.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.

[108]  Y. Taketani,et al.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.

[109]  G. Prescott,et al.  Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study , 2003, BMJ : British Medical Journal.

[110]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[111]  Kenneth J. Hillan,et al.  Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 , 2003, Science.

[112]  A. Hughes,et al.  Pre-eclampsia, antiretroviral therapy, and immune reconstitution , 2002, The Lancet.

[113]  N. Sattar,et al.  Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? , 2002, BMJ : British Medical Journal.

[114]  M. Wolf,et al.  First trimester insulin resistance and subsequent preeclampsia: a prospective study. , 2002, The Journal of clinical endocrinology and metabolism.

[115]  M. Goumans,et al.  Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors , 2002, The EMBO journal.

[116]  Diagnosis and management of preeclampsia and eclampsia , 2002 .

[117]  G. Dekker,et al.  Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia , 2002, The Lancet.

[118]  R. T. Lie,et al.  The interval between pregnancies and the risk of preeclampsia. , 2002, The New England journal of medicine.

[119]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[120]  M. Wolf,et al.  Obesity and preeclampsia: the potential role of inflammation. , 2001 .

[121]  J. Pell,et al.  Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births , 2001, The Lancet.

[122]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[123]  R. Thadhani,et al.  Pulse Pressure and Risk of Preeclampsia: A Prospective Study , 2001, Obstetrics and gynecology.

[124]  C. Berg,et al.  Pregnancy‐Related Mortality From Preeclampsia and Eclampsia , 2001, Obstetrics and gynecology.

[125]  J. Kooner,et al.  Association of maternal endothelial dysfunction with preeclampsia. , 2001, JAMA.

[126]  M. Varner,et al.  Paternal and maternal components of the predisposition to preeclampsia. , 2001, The New England journal of medicine.

[127]  James J. Walker,et al.  Pre-eclampsia , 2000, The Lancet.

[128]  D. Stevenson,et al.  End-tidal carbon monoxide measurements in women with pregnancy-induced hypertension and preeclampsia. , 2000, American journal of obstetrics and gynecology.

[129]  P. Donahoe,et al.  Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[130]  C. O'Herlihy,et al.  Maternal central hemodynamics in hypertensive disorders of pregnancy. , 1999, Obstetrics and gynecology.

[131]  C. Hubel,et al.  Oxidative Stress in the Pathogenesis of Preeclampsia (44447) , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[132]  D. Dumont,et al.  A murine model of hereditary hemorrhagic telangiectasia. , 1999, The Journal of clinical investigation.

[133]  H. V. van Geijn,et al.  Change in paternity: a risk factor for preeclampsia in multiparous women? , 1999, Journal of reproductive immunology.

[134]  A. Conde-Agudelo,et al.  Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. , 1999, American journal of obstetrics and gynecology.

[135]  J. N. Martin,et al.  Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. , 1999, American journal of obstetrics and gynecology.

[136]  M. Marrero,et al.  Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src* , 1999, The Journal of Biological Chemistry.

[137]  R. Dersimonian,et al.  Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. , 1999, JAMA.

[138]  L. Moore,et al.  Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. , 1999, American journal of obstetrics and gynecology.

[139]  G. Wallukat,et al.  Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. , 1999, The Journal of clinical investigation.

[140]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[141]  A. N. Corps,et al.  A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.

[142]  P. Huie,et al.  Nature of glomerular dysfunction in pre-eclampsia1 , 1998 .

[143]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[144]  I. Sargent,et al.  Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre‐eclamptic pregnancies , 1998, British journal of obstetrics and gynaecology.

[145]  K. Lim,et al.  The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. , 1998, American journal of obstetrics and gynecology.

[146]  Vascular Endothelial Growth Factor Induces Endothelial Fenestrations In Vitro , 1998, The Journal of cell biology.

[147]  I. Zachary,et al.  Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.

[148]  I. Johnson,et al.  Loss of endothelium‐dependent relaxation in myometrial resistance arteries in pre‐eclampsia , 1997, British journal of obstetrics and gynaecology.

[149]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[150]  C. Damsky,et al.  Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? , 1997, The Journal of clinical investigation.

[151]  M. Taketo,et al.  TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. , 1996, Developmental biology.

[152]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[153]  H. Laivuori,et al.  Hyperinsulinemia 17 years after preeclamptic first pregnancy. , 1996, The Journal of clinical endocrinology and metabolism.

[154]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[155]  B. Keyt,et al.  Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors , 1996, The Journal of Biological Chemistry.

[156]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[157]  C. Damsky,et al.  Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. , 1996, The Journal of clinical investigation.

[158]  E. Arnoldus,et al.  A reversible posterior leukoencephalopathy syndrome. , 1996, The New England journal of medicine.

[159]  R. Berkowitz,et al.  The Changing Clinical Presentation of Complete Molar Pregnancy , 1995, Obstetrics and gynecology.

[160]  J. Pezzullo,et al.  Placental pathologic features of preterm preeclampsia. , 1995, American journal of obstetrics and gynecology.

[161]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[162]  M. Blombäck,et al.  Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia , 1995 .

[163]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[164]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[165]  R. North,et al.  Uterine Artery Doppler Flow Velocity Waveforms in the Second Trimester for the Prediction of Preeclampsia and Fetal Growth Retardation , 1994, Obstetrics and gynecology.

[166]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[167]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[168]  B. Sibai,et al.  Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) , 1993, American journal of obstetrics and gynecology.

[169]  S. Liu,et al.  Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.

[170]  D. Chan,et al.  Elevated circulating thrombomodulin in severe preeclampsia. , 1993, American journal of obstetrics and gynecology.

[171]  H. Minakami,et al.  Increased levels of plasma thrombomodulin in preeclampsia. , 1993, Gynecologic and obstetric investigation.

[172]  L. Poston,et al.  Abnormal endothelial cell function of resistance arteries from women with preeclampsia. , 1993, American journal of obstetrics and gynecology.

[173]  C. Damsky,et al.  Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. , 1993, The Journal of clinical investigation.

[174]  Caroline,et al.  Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. , 1992, The Journal of clinical investigation.

[175]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[176]  J. Roberts,et al.  High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. , 1991, American journal of obstetrics and gynecology.

[177]  I. Sargent,et al.  Trophoblast deportation in pre‐eclamptic pregnancy , 1991, British journal of obstetrics and gynaecology.

[178]  M. Mitchell,et al.  Maternal plasma level of endothelin is increased in preeclampsia. , 1991, American journal of obstetrics and gynecology.

[179]  D. Maglione Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .

[180]  J. Moake,et al.  Von Willebrand Factor Multimeric Levels and Patterns in Patients With Severe Preeclampsia , 1990, Obstetrics and Gynecology.

[181]  D. Savitz,et al.  An epidemiologic study of contraception and preeclampsia. , 1991, JAMA.

[182]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[183]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[184]  T. Musci,et al.  Preeclampsia: an endothelial cell disorder. , 1989, American journal of obstetrics and gynecology.

[185]  T. Musci,et al.  Mitogenic activity is increased in the sera of preeclamptic women before delivery. , 1988, American journal of obstetrics and gynecology.

[186]  J. Roberts,et al.  Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. , 1988, American journal of obstetrics and gynecology.

[187]  G. FitzGerald,et al.  Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. , 1987, Circulation.

[188]  Ishak Kg,et al.  Liver disease in toxemia of pregnancy. , 1986 .

[189]  K. Ishak,et al.  Liver disease in toxemia of pregnancy. , 1986, The American journal of gastroenterology.

[190]  T. Stubbs,et al.  Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. , 1984, American journal of obstetrics and gynecology.

[191]  L. Weinstein Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. , 1982, American journal of obstetrics and gynecology.

[192]  J. Brown,et al.  Plasma renin, renin substrate, angiotensin II, and aldosterone in hypertensive disease of pregnancy. , 1973, Lancet.

[193]  D. Paintin,et al.  Renin, Angiotensin and Aldosterone Relationships in Normal Pregnancy , 1970, Proceedings of the Royal Society of Medicine.

[194]  M. Rinsler,et al.  Function of Aldosterone in the Metabolism of Sodium and Water in Pregnancy , 1957, British medical journal.